Proteomics International Laboratories (ASX:PIQ) 3-Year EBITDA Growth Rate : -64.30% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories 3-Year EBITDA Growth Rate?

Proteomics International Laboratories's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.03.

During the past 3 years, the average EBITDA Per Share Growth Rate was -64.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -28.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Proteomics International Laboratories was 22.60% per year. The lowest was -64.30% per year. And the median was -9.10% per year.

Competitive Comparison of Proteomics International Laboratories's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Proteomics International Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteomics International Laboratories's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Proteomics International Laboratories's 3-Year EBITDA Growth Rate falls into.

Proteomics International Laboratories 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Proteomics International Laboratories (ASX:PIQ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Proteomics International Laboratories 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteomics International Laboratories (ASX:PIQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009

Website

https://www.proteomics.com.au

Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories (ASX:PIQ) Headlines

No Headlines